Elicio Therapeutics Showcases Groundbreaking Cancer Research Efforts

Elicio Therapeutics Unveils Future Presentations on Cancer Vaccines

Elicio Therapeutics, Inc. (NASDAQ: ELTX), a pioneering biotechnology company, has announced significant upcoming presentations that focus on their innovative mKRAS-specific amphiphile vaccines. These presentations are set to take place in the upcoming months, showcasing the latest advancements in their clinical trials and research efforts.

First Presentation at AACR Special Conference

The initial presentation is scheduled at the American Association for Cancer Research (AACR) Special Conference, which will occur from September 15-18, focusing on advancements in pancreatic cancer research. Esteemed Dr. Eileen O’Reilly from Memorial Sloan Kettering Cancer Center will share insights from the recent Phase I AMPLIFY-7P trial.

Details of the AACR Presentation

Title: Pancreas Cancer 2024: Translating genomic findings into clinical actionability

Presenter: Dr. Eileen M. O’Reilly

Date and Time: September 15, 5:50 p.m. ET

Second Presentation at RAS-Targeted Drug Development Summit

Following this, the second presentation will take place on September 25 at the RAS-Targeted Drug Development Summit. Dr. Pete DeMuth, Chief Scientific Officer at Elicio, will present critical information on the clinical translation of Elicio’s RAS-targeted amphiphile vaccines, focusing on their mKRAS vaccination strategy.

Details of the RAS Summit Presentation

Title: Targeting mKRAS Vaccination to the Lymph Nodes to Promote Anti-tumor Immunity

Presenter: Dr. Peter C. DeMuth

Date and Time: September 25, 11:45 a.m. ET

Third Presentation at Precision Oncology Institute Symposium

The third presentation occurs on October 1 at the Stuart and Molly Sloan Precision Oncology Institute Symposium, where Dr. Christopher Haqq, Executive Vice President and Chief Medical Officer of Elicio, will discuss the Phase I experience with two specific vaccine candidates, ELI-002 2P and ELI-002 7P.

Details of the Precision Oncology Institute Presentation

Title: Amplifying tumor specific immunity through lymph node targeted mKRAS-specific amphiphile vaccine in gastrointestinal tumors

Presenter: Dr. Christopher M. Haqq

Date and Time: October 1, 9:40 a.m. PT

CEO's Insight on Recent Patient Data

Robert Connelly, Elicio’s CEO, expressed his enthusiasm regarding the recent data from patients who received the 7-peptide version of ELI-002. He highlighted that T cell response data corresponded positively with reduced tumor biomarker levels and a lower risk of progression or death. Connelly remarked, "With $43 million raised in funding for 2024, we're optimistic about our potential clinical updates and upcoming results from the AMPLIFY-201 trial. We anticipate sharing further insights in the latter part of this year and an interim analysis from the AMPLIFY-7P randomized Phase 2 trial early next year."

Understanding Elicio Therapeutics

Elicio Therapeutics is addressing some of the most aggressive cancer types through their advanced pipeline of lymph node-targeted immunotherapies. Utilizing their innovative AMP technology, they aim to channel therapeutic payloads directly to lymph nodes, thus enhancing the immune system's natural ability to combat cancer. This approach is designed to educate, activate, and amplify the activity of cancer-specific T cells, vital for recognizing and eliminating tumors effectively.

About the Amphiphile Platform

The company's proprietary Amphiphile (AMP) platform appears to offer promising results by delivering investigational therapeutics specifically to lymph nodes. This targeted delivery intends to significantly improve the immune response’s magnitude and durability, potentially translating into better clinical outcomes compared to traditional methods. Elicio's technology, developed at the Massachusetts Institute of Technology, shows significant promise across various cancer types.

Frequently Asked Questions

What is Elicio Therapeutics known for?

Elicio Therapeutics focuses on developing innovative immunotherapies for aggressive cancers, particularly through their unique amphiphile vaccines.

When will these upcoming presentations occur?

The presentations are scheduled for September 15, September 25, and October 1 in 2024.

Who are the presenters at these conferences?

Dr. Eileen O’Reilly, Dr. Pete DeMuth, and Dr. Christopher Haqq will present at the respective conferences.

What technology does Elicio use in its research?

Elicio utilizes its Amphiphile platform, which allows for targeted delivery of cancer vaccines to the lymph nodes, enhancing the immune response.

How is patient data relevant to Elicio’s research?

Patient data helps Elicio understand the effectiveness of their vaccines, as seen with positive correlations between T cell responses and tumor biomarker reductions.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.